( ) - PDF Free Download

2014. 12 ()

. 2014. 12 () : ( )

I. 1 1. 1 2. 1 3. 2 4. 2 II. 3 1. 3 2. 3 3. 5 III. 7 1. 7 1) 7 2) 12 IV. 17 1. 17 1) 17 2) 18 3) 19 4) 21 5) 22 2. 23 3. AHP 24 4. AHP 28 1) 28

2) 1 : 29 3) 2 : 30 4) 32 5) 3 : 33 V. 36 1. 36 2. 39 1) 39 2) 42 3) 44 VI. 49 1. 49 2. 51 3. 52 4. 53 5. 54 6. 55 7. 56 8. 59 <> AHP 66

[ ] < 1> 4 < 2> 6 < 3> 26 < 4> 28 < 5> 29 < 6> 30 < 7> R&D 31 < 8> 31 < 9> 32 < 10> 32 < 11> AHP 33 < 12> 35 < 13> 51 < 14> 52

... AHP. AHP...

.,, EU. BT 70% BT, IT, NT. IT NT BT, IT, u-health *, u-health Care 2009 1,431 2013 2,539, u-health Care 2010 17 2014 3,0341, 2012 804 2.0%, (, 2014).,, 21,, (, 2005-17).

, 21 BT, IT, NT. BT, NT, IT.,.,,,, (,, 2002)....

2015, R&D,,,. AHP,. AHP 1), 2) R&D, 3), 4), 5) 5. 5,,,. R&D R&D,,,, R&D.,, IT,.

,,, R&D.,,,., R&D,,, <> (.399) R&D (.185) (.172) (.133) (.111).,, R&D. <> () R&D 0.399 0.185 0.172 0.111 0.133 1 2 3 5 4 CR 0.000

(.577), (.215), (.208).. CR (0.399) <> 0.577 1 0.215 2 0.208 3 0.00 R&D R&D (.381), (.208), R&D (.164), (.140), (.107). R&D R&D. <> R&D CR R&D 0.381 1 R&D 0.208 2 0.140 4 (0.185) 0.107 5 0.00 R&D 0.164 3 (.289), IT (.280),

(.256), (.175).. CR (0.172) <> 0.256 3 0.289 1 IT 0.280 2 0.175 4 0.00 (.304), (.285), (.254), R&D (.156).. CR (0.111) <> 0.304 1 0.285 2 0.254 3 R&D 0.156 4 0.00 (.318), (.239), (.234), (.209)..

CR (0.133) <> 0.239 2 0.318 1 0.234 3 0.209 4 0.01 (.230), (.086), (.083), R&D (.070), (.050), IT (.048), (.044), (.042), (.038), (.034). (.032), (.032), (.031), (.030), R&D (.030), (.028), (.028), (.026), (.020), R&D (.017).

AHP..,,....,..

,,. (convergence legislation). ʻ ',.,.,,,.. IT,,,,,. 21 (convergence)

..,.,,,. AHP (.399) R&D (.185),.

1. < 1> 6 (). 1. 2. IT 3. BT, IT, NT < 2> 6 (). 1. R&D < 3> 6 (). 1. 2. < 4> 1 12. 1. 5, 10 31. 2. < 5>

6 (). 1. 3. < 6>. 1. 2. 3. 4. 5. 6. 4. < 7>. 1. 5,,,,. 5. < 8>.

1. 2. 2 3. 4. 5. 6. < 9>. 1. 2., 7. < 10> 25(). 1. 2. 3,. < 11> 21 (). 1.

2. 3. 4. < 12>. 1.. 2.. 8. < 13> 16( ). 1. IT 2. 3.

I.. -,,. 1... 2..... - 1 -

3... AHP.,,. 4... AHP. - 2 -

II. 1) 1. BT IT NT 2,,,,,,.. 2.. BT 70% BT, IT, NT. * 5 12, 2012 (100) 77.6% 4.1, 2010 2.5 2012 1.9 (, 2014). (BT), (genome) *, 2007-2014 25.1%, 2010 17.5% 2020 25% ( 1) 보건산업육성정책, (www.know.or.kr) - 3 -

, 2011 &, 2014). IT NT BT, IT, u-health, u-health Care 2009 1,431 2013 2,539, u-health Care 2010 17 2014 3,0341, 2012 804 2.0%, (, 2014). <1> () 08 12 ( 08~ 12) () 773 959 5.5% 18.9(2.0%) 257 309 4.7% 4.6(1.5%) 222 258 3.8% 7(2.7%) 2,133 2,441 3.4% 49.8(2.0%) 3,385 3,967 4.0% 80.4(2.0%) : KHIDI, 2013. 12 &, 2014., 2009 51.2% 2011 53.7%, 2010 0.78 2012 1.05 34.6%,, 2018 (14%) 2026 (20%), 2003-2012 10 10.32%, GDP 2003 5.2% 2012 7.6% (, 2014). - 4 -

,, 21, (, 2005-17)., (), (+IT ) (, 2014). 3., 21 BT, IT, NT.,., R&D, (, 2005-17)., IT - 5 -

,. (, 2014). <2> ( ) ( ),, IT,,,, -, -,, :, 2014.,,,,, (,,, ) (, 2005-17).,, 21, R&D R&D, R&D 2010 8.04% 2013 7.66%, 50~60% (, 2014). - 6 -

III. 1.,,..,. 1) 2) (1).,. 1990., R&D (Market Oriented Strategic R&D Program), 2) (http://report1004.co.kr) - 7 -

R&D (R&D Program for Small Business), R&D. NIH,, Biodefense, AIDS,... (2) 2001 9 (EC). 2002 1 (Life Sciences & Biotechnology; A Strategy for Europe)' EU.,,, 4. 1984 Framework Programme.,,. - 8 -

,,,,. 1 (R&D tax credit). University Challenge, Science Enterprise Challenge, Faradat Networks, Reach Out Funds, the DTI Enterprise Fund, the Enterprise Management Incentives. (Department of Trade and Industry, DTI),. LINK, SMART (Small Firms Merit Award for Research and Technology), EURECA(European Rescarch Coordination Agency), EU Framework Programmes. 2 1995. 1996-2001 (BioRegio Initiative Program). - 9 -

2001 3 (Aktionsprogramm 'Wissenschafft Maerkte).,,,. (Federal Ministry of Education and Research, BMBF) (Research for the Benefit of Mankind) 2001 NGRN (National Genome Research Network). 3 (Mobilization Program) 1980. (CNRS) (INSERM). 1990 BioAvenir Program,,. 1999 (the French Law on Innovation),, BioAm, 4.,, (Post-Genomics),,,,. - 10 -

,,,,, (,, 2002). BT, NT, IT. (3). (SNP),,.,,,,,.,. 2003 (leading projects) (tailor-made medicine), (regenerative medicine), - 11 -

,..,,,,. 2010 25 1,000. 1990, 1993 1997... 2) 3) (1), 50~60%, 3) 보건산업육성정책, (www.know.or.kr) - 12 -

, ( 2005-17). M&A,, ( 2005-17).,,,, (2010 ). (2),, R&D,, (2010 ).,,, MRI, PACS, X-ray IT MRI,, CT, 10%, 1, 63% R&D - 13 -

, (2015 ).,, (FDA, CE, SDA ), ( 2005-17). 21, R&D IT, BT, NT, ( 2005-17).,, () (MRA),. (3),, (2010 ). R&D - 14 -

30-60% (), 17, 8,, (2015 ).,,,,,,,, ( 2005-17).,,,, (,, 2002).. (4),,,, - 15 -

. R&D R&D, ( 2005-17)., GMP,, ( 47% ) (2010 ).,,,,, (2015 ). - 16 -

IV. 1. 4) 2014,,,, (, 2014 ). 1),. (1),,.,,,,,,,,. (2) 4) 보건산업육성정책, (www.know.or.kr) - 17 -

,, -IT,,,,,. 2) HT HT R&D, HT R&D, HT R&D. (1) (HT) R&D (HT) R&D, R&D R&D R&D, R&D,. R&D,. R&D R&D,,. - 18 -

(2) (HT),, (250),, (12), (51 ), (156),, (170), (117). R&D,,, (11), (14), (10 ),, (44), 4,, (20 ) (10)., (100), (60), (25) R&D (12). 3). - 19 -

(1), R&D IP-BIZ.,.,. (2),,, (CEO), () ( ), (, ) (, ) (). (3), R&D,,,,,, CRO CRO.,, G2G (,, - 20 -

, ). 4),, G2G. (1),, Bio Korea 2014 & Medical Korea 2014 (,,,, ).. (2),,, G2G,. (3), ( 1), (,,, ), (). G2G - 21 -

Total package, IT,,,,,,,,. 5). (1), 3.0,,,., CS. (2),.,,, (IT-Governance). - 22 -

2. 2015, R&D,,, (, 2015 )., AHP 1), 2) R&D, 3), 4), 5) 5., AHP,.. AHP(Analytic Hierarchy Process). 5 20 AHP( ). 3 (1: 2: 3: ). AHP - 23 -

., AHP.,, 9., AHP Expert Choice 2000. 2014 12 1-12 15. (Consistency Ratio). 20% (Inconsistency). AHP (C.R:Consistency Ratio), 10%, 20%. 20%, (C.R) 0.2. 3. AHP 5,,,. R&D R&D,,,, R&D. - 24 -

,, IT,.,,, R&D.,,,. - 25 -

< 3> 1 2 R&D 3 R&D R&D IT R&D < 1>. - 26 -

- 27 - R&D R &D R &D I T R &D < 1> AHP

4. AHP 1) (AHP) 2014 12 1-12 15. 60 46 0.2 25 0.2 21. < 4> 19 90.5 2 9.5 20 0 0.0 30 2 9.5 40 14 66.7 50 5 23.8 60 0 0.0 4 21.1 8 42.1 3 15.8 1 5.3 3 15.8 (, ) 16 76.2 0 0.0 (, ) 2 9.5 3 14.3 0 0.0 0 0.0 0 0.0 0 0.0 21 100.0 1~5 3 14.3 6~10 5 23.8 11~15 7 33.3 16~20 3 14.3 21~25 0 0.0 25 3 14.3-28 -

21 90.5% 9.5%, 50 23.8%, 40 66.7% 30 9.5%. 21.1,% 42.1%, 15.8%, 5.3%. 76.2%, 14.3%, 9.5%, 11-15 33.3% 6-10 23.8%. 1~5, 16~20, 25 14.3%. 2) 1 :, R&D,,, < 5> (.399) R&D (.185) (.172) (.133) (.111).,, R&D. < 5> () R&D 0.399 0.185 0.172 0.111 0.133 1 2 3 5 4 CR 0.000-29 -

3) 2 :, (.577), (.215), (.208).. CR (0.399) < 6> 0.577 1 0.215 2 0.208 3 0.00, R&D R&D (.381), (.208), R&D (.164), (.140), (.107). R&D R&D. - 30 -

< 7> R&D CR R&D 0.381 1 R&D 0.208 2 0.140 4 (0.185) 0.107 5 0.00 R&D 0.164 3, (.289), IT (.280), (.256), (.175).. CR (0.172) < 8> 0.256 3 0.289 1 IT 0.280 2 0.175 4 0.00, (.304), (.285), (.254), R&D (.156).. - 31 -

CR (0.111) < 9> 0.304 1 0.285 2 0.254 3 R&D 0.156 4 0.00, (.318), (.239), (.234), (.209).. CR (0.133) < 10> 0.239 2 0.318 1 0.234 3 0.209 4 0.01 4), R&D 2.16063, 2.52926, 3.41021, 2.8785. R&D 1.12477, 1.6808, 1.33327. - 32 -

1.69152, 1.33868 1.15247. < 11> AHP (CR: 0.01) R&D R&D 2.16063 2.52926 3.41021 2.8785 1.12477 1.6808 1.33327 1.69152 1.33868 1.15247 5) 3 : (.230), (.086), (.083), R&D (.070), (.050), IT (.048), (.044), (.042), (.038), (.034). - 33 -

(.032), (.032), (.031), (.030), R&D (.030), (.028), (.028), (.026), (.020), R&D (.017). - 34 -

< 12> (CR : 0.01) (0.399) 0.577 1 0.230 1 0.215 2 0.086 2 0.208 3 0.083 3 R&D 0.381 1 0.070 4 R&D (0.185) 0.208 2 0.038 9 0.140 4 0.026 18 0.107 5 0.020 19 R&D 0.164 3 0.030 14 (0.172) 0.256 3 0.044 7 0.289 1 0.050 5 IT 0.280 2 0.048 6 0.175 4 0.030 14 0.304 1 0.034 10 (0.111) 0.285 2 0.032 11 0.254 3 0.028 16 R&D 0.156 4 0.017 20 (0.133) 0.239 2 0.032 11 0.318 1 0.042 8 0.234 3 0.031 13 0.209 4 0.028 16-35 -

V. 1. AHP,...,,.,. ㆍ ( 整合性 ),,. (, 2000). - 36 -

, (, 2000)..,,,, (, 2000).. 21,..., (, 2000).,,,,.,, - 37 -

(, 2000).,,.,,.,.....,,. - 38 -

2. 1) 5) 42. 2008,, 2012, UAE,, 422600 3.. 6. 2013 717 1,, 2013 10 (KOTRA) (KOICA) 25 118,,,. 5)http://news.kukinews.com/article/view.asp?arcid=0008782336&code=46111201&cp=nv - 39 -

,,., 6 (HIS) 7000.. HIS 4 MOU.. 14, 2012 MOU, 2012 4 9, 2013 2, 2013 6. - 40 -

2013 9.,. 2011.,..,. - 41 -

2).,,.,.,...,,. - 42 -

,,,.,.,.,,.,,..,,. (, 2013).,, ( 數 ),.,, - 43 -

(, 2013).,. (, 2013). 3) (convergence legislation).,,..,,,.. - 44 -

3.0, 3.0,,,,,,,.,,, 3.0.. 21 (convergence).., ʼ (,, 2011. 9.), ʼ - 45 -

26.7%, ʻ ʼ ʻ ʼ 51.5% ʻ ʼ 14.6% 66.1%. 70%,,. U. 2011 10,,.....,. - 46 -

,... 2003,,. 2001 2009, 2010,,,,, 5 ( 法務省, 2010). ZIP(zero in process), 21 ZIP,,,, ZIP (, 2008). - 47 -

.. 5, 9 10, (, 2004). IT,,.,,,.,.,,,.,,,. - 48 -

VI. 1. 6. 6 () 1. 2003.5.29, 2006. 10.27, 2008.3.28 1. 2008.3.28 2. ㆍ 3. ㆍ 4. ㆍㆍ ㆍ ㆍ 5. ㆍㆍ 2008.3.28 6. ㆍ 7. 8. 2006. 10.27 9. 87 2006. 10.27 2008.3.28, 2008.9.28 10. <8 2006.10.27> 11. 1 10 2006. 10.27, 2008.3.28.., - 49 -

.,.,., 21, (29.2%) (41.3%), ( 15%)., R&D, R&D R&D AHP. < 1> 6 (). 1. 2. IT 3. BT, IT, NT < 2> 6 (). 1. R&D < 3> 6 (). - 50 -

1. 2. < 4> 1 12. 1. 5, 10 31. 2. (2001 77) (2004 1.16)., 1 2000 61 2020 339, 2050 2904. 1 2000 85 2020 478, 2050 5273. 2001 17% 24% 2019 65 65 < 13> 2001 2010 2020 33 74 171 GDP 6.1% 8.1% 11.4% - 51 -

. 7%() 14%() 18 14% 20%() 8.. < 14> (: ) 19 24 71 115 85 2000 1970 1942 1864 1890 2019 1994 2013 197 1975 : 1. UN, The Sex and Age Distribution of World Population,. 2.,, 2000. 3.,, 2001.. 10% 30~50%. 7~8%.. < 5> 6 (). 1. 3.,,,, - 52 -

,... < 6>. 1. 2. 3. 4. 5. 6. 4. HT Initiative (2012~2016) 4 5..,.,.,, - 53 -

. NIH,.,,,.. < 7>. 1. 5,,,,. 5. 2 6. 6() 1 ( "" ). < 2010.1.18., 2013.7.30.> 2. < 2013.7.30.> 1. 2. 3. 4. 5. 6. - 54 -

7. 8. 3 2. 4. 5.. (:). < 8>. 1. 2. 2 3. 4. 5. 6. 4 3. 4( ) 3. < 2013.7.30.> - 55 -

1. 2. 3. 4. 5. ( 需給 ) 6..,,... < 9>. 1. 2., 7. 25. 25() 1,,. 2. < 2011.8.4.> 3 1-56 -

. [21, 25 29 <2011.8.4.>],.,... < 10> 25(). 1. 2. 3,. 21. 21(). < 2013.7.30.> 1. 2. 3. 4. 5. - 57 -

6. 7. [17, 21 25 <2011.8.4.>],..,. < 11> 21 (). 1. 2. 3. 4. < 12>. 1.. 2.. - 58 -

8. 3 16. 16( ) 151. 1. 3,. 2.. [ 2011.8.4.] [ 16 20 <2011.8.4.>] AHP 3,... < 13> 16( ). 1. IT 2. 3. - 59 -

,,, 15 1, 2 004. 法務省, 平成 21 年度法務省事後評価実施結果報告書, 2010. 9., -, 2000. 7.,, 2008, 12., (), APEXPH: Assessment Protocol for Excellence in Public Health, The National Association of County Health Officials,, 1998.,, (www.know.or.kr), - 2013. 2., - -, 2012. 10., 2005-17,, 2005.,, 2005., 2005,, 2005. 3.,,, 2005. 3., BT,, 2004. 12., BT R&D,, 2005. 5.,,, 2005. 6.,,, 2003. 6.,,, 2003., 10,, 2001. 2.,,, 2001.,,, 2001., 2014,, 2014., (2015-2019),, 2014., 2015,, 2007., 2010,, 2006.,,, 2005.,,, 2005.,,, 2004. - 60 -

,,, 2004.,,, 2004., 2004,, 2003.,,, 2002. 5., (A Research on the Actual Condition of Health Industry and the Ripple on National Economy),, 2002.,,, 2002.,, 2002., MRA (/ MRA ),, 2000. 12.,,, 1999,,, 2014. 2. R&D, R&D,, 2013. 5. http://report1004.co.kr() http://news.kukinews.com/article/view.asp?arcid=0008782336&code=46111201&cp=nv - 61 -

() ( 2014.1.31.) ( 11975. 2013.7.30. ) [] BT, NT, ICT ㆍ,,,,, ㆍ ㆍ,, ㆍ.. ㆍ 5 ㆍ ( 4).. ㆍ ㆍ ㆍ ( 72 73 ).. ( 152 153 ).. ( 21).., ( 26). - 62 -

11975. 21 8. 8. " " ㆍ( ㆍ )............ 1 22. 22( ) ㆍ. 4 "( )" "( )", 1 2, 3 " " "", 6, 4 6. 1 ㆍ 5 ( " " ). 2 91 ( "" ). 6. 4 ( "" ). 5 6. 6. - 63 -

5 "" " ", 1 "" "". 61 "" "", 21, 7 8, 7. 1. 7. 72 73. 72( ) 1 ㆍㆍ ㆍ ㆍ. 2 1. 73( ㆍ) ㆍ. 87 "1" "1 6". 153 " 2 " " 3 2 ", 4 "3 " "3 ". 152 153. 152( ) 1 15. 1. 2. 3. 2. 153() 15211. 191 " " " ". 21. - 64 -

1. ㆍ ㆍㆍ 2. 3. 4. ㆍ 5. 6. ㆍ ㆍ ㆍ 7. 262, 3 4. 2 1 23 24.. 3 2.. 4 1 3.., 4 72 6. - 65 -

- 2010 HT - AHP [ ] - 66 -

? 2020 HT,. AHP(Analytic Hierarchy Process),.,,,... 2014 11 *. eungeeyun@naver.com - 67 -

R&D (,, ) (, HT 新 ) ( (Evidence-Based), ) R&D ( R&D 新 R&D, R&D ) ( ㆍ ) (, ) ( ) R&D ( R&D -, R&D ) (,,,,, (New excellent technology, NET) ) (,,, ) IT ( 7, IT, IT ) (,, ) (, ) (, - 68 -

) (,, ) R&D ( R&D, G2G R&D R&D ) ( ) ( ) (,, ) ( 新, ) - 69 -

< > 1. 3 5 7 9 2, 4, 6, 8 1, 3, 5, 7, 9 < > 1 (A) 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 (B) A B.,, (A) (B), (1) (A) 7 ( ). - 70 -

5., A B, B C, A C. 1. 1 2 3 4 5 6 7 8 9 10 R&D R&D R&D 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 R&D - 71 -

., A B, B C, A C. 2. 1 2 3 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9-72 -

3. R&D 1 2 3 4 5 6 7 8 9 10 R&D R&D R&D R&D 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 R&D R&D R&D R&D - 73 -

4. 1 2 3 4 5 6 IT 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 IT IT 5. 1 2 3 4 5 6 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 R&D R&D R&D - 74 -

6. 1 2 3 4 5 6 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 9 8 7 6 5 4 3 2 1 2 3 4 5 6 7 8 9 / 1 2 3 4 5 6 ( ) 1 (, ) 2 3 (, ) 4 5 6 ( ) 1 2 3 1 1-5 2 6-10 3 11-15 4 16-20 5 21-25 6 25 1 20 2 30 3 40 4 50 5 60-75 -